Drug Trial Radar · NCT00506415
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Last checked: Nov 20, 2026Latest source record: Sep 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,584
Actual
Start
Jun 2007
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.
Conditions
- Alzheimer Disease
Interventions
Rivastigmine 5 cm^2Drug
5 cm\^2 transdermal patch
Rivastigmine 10 cm^2Drug
10 cm\^2 transdermal patch.
Rivastigmine 15 cm^2Drug
15 cm\^2 transdermal patch.
Placebo to 15 cm^2 patchDrug
Placebo of rivastigmine transdermal patch 15 cm\^2.
Placebo to 10 cm^2 patchDrug
Placebo of rivastigmine transdermal patch 10 cm\^2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind PeriodTime frame: Baseline and week 48 of double blind period
- Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind PeriodTime frame: Baseline and week 48 of double blind period
Locations
145 sites in 7 countries. Site status is shown where the registry gives one.
Novartis investigative site
Birmingham, Alabama
Novartis investigative site
Gilbert, Arizona
Novartis investigative site
Phoenix, Arizona
Novartis investigative site
Sun City, Arizona
Novartis investigative site
Anaheim, California
Novartis investigative site
Carson, California
Novartis investigative site
Costa Mesa, California
Novartis investigative site
Fullerton, California
Novartis investigative site
La Habra, California
Novartis investigative site
La Jolla, California
Novartis investigative site
National City, California
Novartis investigative site
Redlands, California
Novartis investigative site
San Francisco, California
Novartis investigative site
Fort Collins, Colorado
Novartis investigative site
Longmont, Colorado
Novartis investigative site
Boca Raton, Florida
Novartis investigative site
Bradenton, Florida
Novartis investigative site
Deerfield Beach, Florida
Novartis investigative site
Delray Beach, Florida
Novartis investigative site
Fort Lauderdale, Florida
Novartis investigative site
Gainesville, Florida
Novartis investigative site
Miami Beach, Florida
Novartis investigative site
Pompano Beach, Florida
Novartis investigative site
Port Charlotte, Florida
Novartis investigative site
Sunrise, Florida
Novartis investigative site
West Palm Beach, Florida
Novartis investigative site
Atlanta, Georgia
Novartis investigative site
Macon, Georgia
Novartis Investigative Site
Honolulu, Hawaii
Novartis investigative site
Chicago, Illinois
Novartis investigative site
Springfield, Massachusetts
Novartis investigative site
Flint, Michigan
Novartis investigative site
Flushing, Michigan
Novartis investigative site
Roseville, Michigan
Novartis investigative site
Traverse City, Michigan
Novartis investigative site
Hattiesburg, Mississippi
Novartis investigative site
Ocean Springs, Mississippi
Novartis investigative site
Columbia, Missouri
Novartis investigative site
St Louis, Missouri
Novartis investigative site
Flemington, New Jersey
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.